Everolimus-eluting stent implantation for unprotected left main coronary artery stenosis: The PRECOMBAT-2 (premier of randomized comparison of bypass surgery versus angioplasty using sirolimus-eluting stent in patients with left main coronary artery disease) study

Young Hak Kim, Duk Woo Park, Jung Min Ahn, Sung Cheol Yun, Hae Geun Song, Jong Young Lee, Won Jang Kim, Soo Jin Kang, Seung Whan Lee, Cheol Whan Lee, Seong Wook Park, Yangsoo Jang, Myung Ho Jeong, Hyo Soo Kim, Seung Ho Hur, Seung Woon Rha, Do Sun Lim, Sung Ho Her, Ki Bae Seung, In Whan SeongSeung Jung Park

    Research output: Contribution to journalArticlepeer-review

    76 Citations (Scopus)

    Abstract

    Objectives: This study sought to evaluate the safety and efficacy of second-generation drug-eluting stents (DES) for patients with unprotected left main coronary artery (ULMCA) stenosis. Background: The clinical benefit of second-generation DES for ULMCA stenosis has not been determined. Methods: The authors assessed 334 consecutive patients who received everolimus-eluting stents (EES) for ULMCA stenosis between 2009 and 2010. The 18-month incidence rates of major adverse cardiac or cerebrovascular events (MACCE), including death, myocardial infarction (MI), stroke, or ischemia-driven target vessel revascularization (TVR), were compared with those of a randomized study comparing patients who received sirolimus-eluting stents (SES) (n = 327) or coronary artery bypass grafts (CABG) (n = 272). Results: EES (8.9%) showed a comparable incidence of MACCE as SES (10.8%; adjusted hazard ratio [aHR] of EES: 0.84; 95% confidence interval [CI]: 0.51 to 1.40; p = 0.51) and CABG (6.7%, aHR of EES: 1.40; 95% CI: 0.78 to 2.54; p = 0.26). The composite incidence of death, MI, or stroke also did not differ among patients receiving EES (3.3%), SES (3.7%; aHR of EES: 0.63; 95% CI: 0.27 to 1.47; p = 0.29), and CABG (4.8%; aHR of EES: 0.67; 95% CI: 0.29 to 1.54; p = 0.34). However, the incidence of ischemia-driven TVR in the EES group (6.5%) was higher than in the CABG group (2.6%, aHR of EES: 2.77; 95% CI: 1.17 to 6.58; p = 0.02), but comparable to SES (8.2%, aHR of EES: 1.14; 95% CI: 0.64 to 2.06; p = 0.65). Angiographic restenosis rates were similar in the SES and EES groups (13.8% vs. 9.2%, p = 0.16). Conclusions: Second-generation EES had a similar 18-month risk of MACCE for ULMCA stenosis as first-generation SES or CABG. (Evaluation of Outcomes of EES Implantation for Unprotected Left Main Coronary Artery Stenosis [PRECOMBAT-2]; NCT01348022)

    Original languageEnglish
    Pages (from-to)708-717
    Number of pages10
    JournalJACC: Cardiovascular Interventions
    Volume5
    Issue number7
    DOIs
    Publication statusPublished - 2012 Jul

    Bibliographical note

    Funding Information:
    This study was supported by funds from the Abbott Vascular, Santa Clara, California, Healthcare Technology R&D Project, Ministry of Health & Welfare , Republic of Korea ( A102065 ) and Cardiovascular Research Foundation. Dr. S. J. Park has received research grants from Cordis and Abbott . Dr. Y. H. Kim has received honoraria from Boston Scientific. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

    Keywords

    • bypass surgery
    • coronary disease
    • left main coronary disease
    • stents

    ASJC Scopus subject areas

    • Cardiology and Cardiovascular Medicine

    Fingerprint

    Dive into the research topics of 'Everolimus-eluting stent implantation for unprotected left main coronary artery stenosis: The PRECOMBAT-2 (premier of randomized comparison of bypass surgery versus angioplasty using sirolimus-eluting stent in patients with left main coronary artery disease) study'. Together they form a unique fingerprint.

    Cite this